Primary Sclerosing Cholangitis Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight

February 07 01:52 2023
Primary Sclerosing Cholangitis Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight
DelveInsight’s, “Primary Sclerosing Cholangitis – Pipeline Insight, 2023,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s Primary Sclerosing Cholangitis Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Primary Sclerosing Cholangitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Primary Sclerosing Cholangitis pipeline domain.


Key Takeaways from the Primary Sclerosing Cholangitis Pipeline Report

  • Over 14+ Primary Sclerosing Cholangitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Primary Sclerosing Cholangitis market would significantly increase market revenue. 
  • Leading Primary Sclerosing Cholangitis companies developing novel drug candidates to improve the Primary Sclerosing Cholangitis treatment landscape include Gilead Sciences, Immunic, and others.
  • Promising Primary Sclerosing Cholangitis pipeline therapies in various stages of development include GS-9674, IMU-838, and others.


Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The condition may lead to cirrhosis of the liver with portal hypertension and end-stage liver disease (ESLD). The main symptoms of primary sclerosing cholangitis (PSC) are feeling tired or weak and having itchy skin. 

Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen. The cause of PSC is not known. A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests. 

Diagnosis is done by cholangiography (magnetic resonance cholangiopancreatography [MRCP] or endoscopic retrograde cholangiopathy [ERCP]). Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies.


Request for a sample report to know more about the Primary Sclerosing Cholangitis treatment algorithm and diagnosis.


Primary Sclerosing Cholangitis Pipeline Analysis: Drug Profile

GS-9674: Gilead Sciences

GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.


Discover more about the emerging Primary Sclerosing Cholangitis drugs @ Primary Sclerosing Cholangitis Treatment Drugs


Primary Sclerosing Cholangitis Key Companies

  • Gilead Sciences
  • Immunic


Primary Sclerosing Cholangitis Pipeline Therapies

  • GS-9674
  • IMU-838


Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 


Scope of the Primary Sclerosing Cholangitis Pipeline Report 

  • Coverage: Global 
  • Key Primary Sclerosing Cholangitis Companies: Gilead Sciences, Immunic, and others
  • Key Primary Sclerosing Cholangitis Pipeline Therapies: GS-9674, IMU-838, and others


Find out more about the Primary Sclerosing Cholangitis treatment options in development @ Primary Sclerosing Cholangitis Clinical Trials


Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight


Other Trending Reports:

  • Asthma Diagnostic Devices Market
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market
  • Airway Management Devices Market
  • Cough Assist Devices Market
  • Pulse Oximeters Market
  • Hemodialysis Catheter Devices Market
  • Chronic Spontaneous Urticaria Market 
  • Gender Dysphoria Market
  • Germany Healthcare Outlook
  • Biopsy Devices Pipeline Insight
  • Bacterial Conjunctivitis Market
  • Infliximab Biosimilar Insight
  • Eosinophilic Asthma Market
  • Cushing Syndrome Market


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 


Contact Us

Kritika Rehani

[email protected] 


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States